These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 11743357

  • 1. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK.
    J Urol; 2002 Jan; 167(1):364-7. PubMed ID: 11743357
    [Abstract] [Full Text] [Related]

  • 2. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, De La Taille A, Abbou CC, Chopin DK.
    J Urol; 2001 Dec; 166(6):2142-7. PubMed ID: 11696723
    [Abstract] [Full Text] [Related]

  • 3. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 4. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM, de Boer EC, Kurth KH, Schamhart DH.
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [Abstract] [Full Text] [Related]

  • 5. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M, Koga H, Noma H, Yamaguchi A, Yoshikai Y, Naito S.
    Urol Int; 2005 Feb; 75(2):114-8. PubMed ID: 16123563
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression.
    Thalmann GN, Dewald B, Baggiolini M, Studer UE.
    J Urol; 1997 Oct; 158(4):1340-4. PubMed ID: 9302115
    [Abstract] [Full Text] [Related]

  • 7. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR, Drowart A, Van Vooren JP, de Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman CC, Huygen K.
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [Abstract] [Full Text] [Related]

  • 8. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T.
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [Abstract] [Full Text] [Related]

  • 9. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P, Holmäng S.
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [Abstract] [Full Text] [Related]

  • 10. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 11. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
    Griffiths TR, Charlton M, Neal DE, Powell PH.
    J Urol; 2002 Jun; 167(6):2408-12. PubMed ID: 11992047
    [Abstract] [Full Text] [Related]

  • 12. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
    Poppas DP, Pavlovich CP, Folkman J, Voest EE, Chen X, Luster AD, O'Donnell MA.
    Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
    Okamura T, Akita H, Imura M, Kaneko T, Mizuno K, Tozawa K, Kohri K.
    Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
    [Abstract] [Full Text] [Related]

  • 14. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, Popov Z, Zafrani ES, Abbou CC, Chopin DK, de Medina SG.
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [Abstract] [Full Text] [Related]

  • 15. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 16. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y, BCG Tokyo 172 Strain Study Group.
    Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
    [Abstract] [Full Text] [Related]

  • 17. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM.
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [Abstract] [Full Text] [Related]

  • 18. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
    Kondylis FI, Demirci S, Ladaga L, Kolm P, Schellhammer PF.
    J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479
    [Abstract] [Full Text] [Related]

  • 19. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy.
    Saint F, Kurth N, Maille P, Vordos D, Hoznek A, Soyeux P, Patard JJ, Abbou CC, Chopin DK.
    Int J Cancer; 2003 Nov 10; 107(3):434-40. PubMed ID: 14506744
    [Abstract] [Full Text] [Related]

  • 20. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
    J Urol; 2005 Feb 10; 173(2):405-9. PubMed ID: 15643181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.